Department of Radiation Oncology, Radiotherapeutisch Instituut Stedendriehoek en Omstreken (RISO), Deventer, The Netherlands.
Strahlenther Onkol. 2011 Aug;187(8):499-501. doi: 10.1007/s00066-011-2232-8. Epub 2011 Jul 25.
Erlotinib is an epidermal growth factor receptor inhibitor prescribed to patients with locally advanced or metastasized non-small cell lung carcinoma after failure of at least one earlier chemotherapy treatment. Approximately 75% of the patients treated with erlotinib develop acneiform skin rashes.
A patient treated with erlotinib 3 months after finishing concomitant treatment with chemotherapy and radiotherapy for non-small cell lung cancer is presented. Unexpectedly, the part of the skin that had been included in his previously radiotherapy field was completely spared from the erlotinib-induced acneiform skin rash.
The exact mechanism of erlotinib-induced rash sparing in previously irradiated skin is unclear. The underlying mechanism of this phenomenon needs to be explored further, because the number of patients being treated with a combination of both therapeutic modalities is increasing. The therapeutic effect of erlotinib in the area of the previously irradiated lesion should be assessed.
厄洛替尼是一种表皮生长因子受体抑制剂，适用于至少一种早期化疗治疗失败后的局部晚期或转移性非小细胞肺癌患者。大约 75%接受厄洛替尼治疗的患者会出现痤疮样皮疹。
本文介绍了一位接受厄洛替尼治疗的患者，他在接受化疗和放疗治疗非小细胞肺癌 3 个月后出现这种情况。出乎意料的是，他之前接受放射治疗的皮肤区域中包含的那部分皮肤完全没有出现厄洛替尼引起的痤疮样皮疹。
厄洛替尼引起的皮疹在先前照射过的皮肤中出现的具体机制尚不清楚。需要进一步探讨这种现象的潜在机制，因为同时接受这两种治疗方式的患者数量正在增加。应评估厄洛替尼在先前照射病变区域的治疗效果。
